Division of Ipsen
Latest From Tercica Inc.
The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.
Ipsen achieved a milestone in its 10-month-old plan to double sales revenue by 2020 by focusing on specialty drug niches and expanding its global presence when the French biotechnology company opened its new US commercial headquarters on 25 April.
As part of an ongoing strategic reorganization, Ipsen announced the appointment of a nine-member U.S. leadership team to execute on the growth of its neurology and endocrinology franchises.
As part of its strategy to increase its presence in the US, Paris drug maker Ipsen is moving its North American headquarters cross-country from California to New Jersey under a plan that also includes a $45 million expansion of its Massachusetts R&D and manufacturing facilities and the hiring of 117 new employees.
- Therapeutic Areas
- Metabolic Disorders
- Tercica Medica Inc.
- North America
- Parent & Subsidiaries
- Senior Management
- Contact Info
Phone: (650) 624-4900
2000 Sierra Pt. Pkwy.
Brisbane, CA 94005
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.